Autres langues Johnson & Johnson Mexican S.E.

Actions

JNJ *

US4781601046

Cours en clôture Mexican S.E. Autres places de cotation 00:00:00 03/06/2024			Varia. 5j.	Varia. 1 janv.
2 490 ^MXN	0,00%		+0,59%	-5,89%

02:36	J&J doit payer 260 millions de dollars dans le dernier procès sur le talc, selon un jury de l'Oregon	RE
03/06	Johnson & Johnson annonce les résultats de l'étude de phase 3 PERSEUS	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

J&J must pay $260 million in latest talc trial, Oregon jury says	02:36
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	03/06
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	03/06
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	03/06
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	03/06
GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06
Johnson & Johnson Announces First Data from the Phase 3 PALOMA-3 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib	31/05
Sector Update: Health Care Stocks Higher Late Afternoon	31/05
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	31/05
Sector Update: Health Care Stocks Advance Friday Afternoon	31/05
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars	31/05
J&J : finalise l'acquisition de Shockwave Medical	31/05
Johnson & Johnson Closes Acquisition of Shockwave Medical	31/05
Johnson & Johnson completed the acquisition of Shockwave Medical, Inc. from a group of sellers.	31/05
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	30/05
Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM	29/05
J&J : résultats encourageants dans le soin de la dépression	29/05
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	29/05
J&J's treatment for depression succeeds in late stage study	29/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30